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Several common biological properties between cancer cells and embryonic stem (ES) 
cells suggest the possibility that some genes expressed in ES cells might play important 
roles in cancer cell growth.  The transcription factor ZFP57 is expressed in 
self-renewing ES cells and its expression level decreases during ES cell differentiation.  
This study showed that ZFP57 is involved in the anchorage-independent growth of 
human fibrosarcoma HT1080 cells in soft agar.  ZFP57 overexpression enhanced, 
while knockdown suppressed, HT1080 tumor formation in nude mice.  Furthermore, 
ZFP57 regulates the expression of IGF2, which plays a critical role in ZFP57-induced 
anchorage-independent growth.  ZFP57 also promotes anchorage-independent growth 
in ES cells and immortal fibroblasts.  Finally, immunohistochemical analysis revealed 
that ZFP57 is overexpressed in human cancer clinical specimens.  Taken together, 






Embryonic stem (ES) cells are derived from pluripotent cells of the early mammalian 
embryo and are capable of unlimited, undifferentiated proliferation in vitro.1,2  
Leukemia inhibitory factor (LIF) can maintain the self-renewal and pluripotency of 
mouse ES cells.3  Similarly, several transcription factors play important roles in the 
self-renewal of ES cells.4  For example, the POU-family transcription factor Oct3/4 is 
an essential player in self-renewal and often acts together with the SRY-related 
HMG-box protein Sox2 to regulate the expression of transcription factors important to 
self-renewal.5-7  Nanog is a homeobox transcription factor whose overexpression can 
bypass the requirement for LIF in self-renewal, although it is dispensable for 
self-renewal.8-10  Extensive studies have revealed that these transcription factors form 
networks and stimulate the expression of a set of genes that maintain self-renewal in ES 
cells.11,12   
Interestingly, ES cells share many biological properties with cancer cells.  For 
example, when injected into nude mice, ES and cancer cells can produce benign and 
malignant tumors, respectively.  Both cell types have a rapid cell cycle.  Telomerase 
activity is very high in both cells, which allows them to proliferate indefinitely.  In 
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addition, several signal transduction pathways seem to be commonly used in both ES 
cell self-renewal and cancer cell growth.13,14  For example, the STAT3 pathway, which 
plays a central role in ES cell self-renewal,15,16 is activated in several types of cancer 
cells.17  The Wnt/β-catenin pathway, whose activation is associated with tumorigenesis 
in many tissues,18 is involved in ES cell self-renewal.19-21  Gli, a central signaling 
molecule in the Hedgehog pathway that is activated in a broad spectrum of human 
tumors,22 promotes the maintenance of ES cells.23  These similarities have raised the 
possibility that some molecules involved in ES cell self-renewal may play important 
roles in cancer cell growth and encouraged us to search for an oncogene in 
self-renewing ES cells.   
 Here, we report the involvement of the ES-specific transcription factor ZFP57 
in cancer cell growth.  We demonstrate that ZFP57 is involved in the 
anchorage-independent growth of human fibrosarcoma HT1080 cells both in vitro and 
in vivo and that it acts by regulating the expression of insulin-like growth factor 2 
(IGF2).  In addition, we show that this transcription factor is also involved in the 
growth of mouse ES cells in soft agar and can stimulate the anchorage-independent 
growth of mouse NIH3T3 cells.  Furthermore, we observed the overexpression of 








Search for stem cell genes that promote anchorage-independent growth in HT1080 
cells 
To identify stem cell genes involved in tumor growth, we cloned several genes from 
self-renewing mouse ES cells and examined the effect of their ectopic expression on 
anchorage-independent growth, a property of cancer cells important for tumor formation 
(Supplementary Figure S1).  As a result, we found that Lrh1 (also known as Nr5a2), 
Nanog and Zfp57 can promote anchorage-independent growth in human fibrosarcoma 
HT1080 cells.  The involvement of LRH1 and NANOG in tumor growth has already 
been reported.24,25  In this study, therefore, we focused our attention on ZFP57.   
 
Involvement of ZFP57 in the anchorage-independent growth of HT1080 cells 
Since we used mouse Zfp57 for screening, we first confirmed that human ZFP57 also 
promotes anchorage-independent growth.  As shown in Figures 1a-c, overexpression 
of human ZFP57 enhanced the growth of HT1080 cells in soft agar.   We next 
examined the requirement of ZFP57 for anchorage-independent growth in HT1080 cells 
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by knockdown experiments using artificial micro RNA (miRNA) against ZFP57.  To 
avoid any off-target effect, we used two independent ZFP57 miRNA constructs, ZFP57 
miRNA(349) and ZFP57 miRNA(427).  Quantitative RT-PCR confirmed that both 
ZFP57 miRNAs suppress the expression of endogenous ZFP57 mRNA (Figure 3b).  
Using these miRNAs, we found that ZFP57 knockdown suppresses the growth of 
HT1080 in soft agar (Figure 1d).  We confirmed that the suppression of soft agar 
growth by ZFP57 miRNA can be restored by overexpression of Zfp57 (Supplementary 
Figure S2).  These results suggest that ZFP57 is involved in the 
anchorage-independent growth of HT1080 cells. 
 
ZFP57 is involved in tumor formation in nude mice 
To determine whether ZFP57 is required for anchorage-independent growth in HT1080 
cells in vivo, we established a HT1080 transfectant in which ZFP57 can be knocked 
down by the addition of 4-hydroxytamoxifen (4-HT) (Supplementary Figure S3).  We 
confirmed that 4-HT treatment reduces the expression of ZFP57 and suppresses growth 
in soft agar.  After pretreatment with 4-HT, we implanted the transfectant cells into 
nude mice subcutaneously and measured the size of HT1080-derived tumors.  We 
observed that the depletion of ZFP57 suppresses tumor growth in nude mice (Figure 2a).  
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We next examined the effect of ZFP57 overexpression on HT1080 tumor formation.  
As in the case of in vitro experiments, we observed that the overexpression of ZFP57 
promotes tumor growth in vivo (Figure 2b).  Overexpression of ZFP57 in the resulting 
tumors was confirmed by quantitative RT-PCR (Supplementary Figure S4).  These 
results indicate that ZFP57 is involved in anchorage-independent growth in HT1080 
cells both in vitro and in vivo.   
 
IGF2 is a downstream gene of ZFP57 
To elucidate the molecular mechanism behind ZFP57-mediated anchorage-independent 
growth, we searched for a target gene of ZFP57.  In embryo and ES cells, Zfp57 
regulates the expression of a variety of imprinted genes.26,27  Among imprinted genes, 
IGF2 is involved in tumorigenesis in various cancers.28,29  We therefore explored the 
possibility that IGF2 may be a downstream gene of ZFP57 in HT1080 cells.   
Based on previous reports showing binding of ZFP57 to the imprinting control 
region (ICR) of IGF2-H19 in ES cells,27 we first examined whether the same was true in 
HT1080 cells.  ChIP analysis revealed that ZFP57 binds to the region containing the 
ZFP57-binding motif within the IGF2-H19 ICR in HT1080 cells (Figure 3a).  
Furthermore, we found that IGF2 expression is suppressed upon knockdown of ZFP57 
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(Figure 3b).  We confirmed that the ZFP57 knockdown-mediated suppression of IGF2 
expression can be recovered by Zfp57 overexpression (Supplementary Figure S5).  
These results suggest that ZFP57 regulates IGF2 expression in HT1080 cells. 
 
IGF2 is required for anchorage-independent growth in HT1080 cells 
Since we identified IGF2 as a downstream gene of ZFP57, we explored the possibility 
that IGF2 may be required for the ZFP57-mediated anchorage-independent growth of 
HT1080 cells.   
Firstly, we assessed the existence of functional IGF2 signaling in HT1080 cells.  
To induce cell proliferation and survival, IGF2 must bind to the IGF1 receptor and 
thereby activate AKT.28,29  Western blot analysis revealed that the IGF1 receptor is 
expressed in HT1080 cells (Figure 4a).  When we stimulated HT1080 cells with 
recombinant human IGF2 in serum-free conditions, we observed AKT phosphorylation 
at Thr-308 and Ser-473, indicating activation of AKT (Figure 4b).  These observations 
suggest that the IGF2 signaling pathway is functional in HT1080 cells.   
Next, we examined the effect of ZFP57 knockdown on the phosphorylation 
status of AKT.  When we compared the amount of phosphorylated AKT between 
ZFP57 knockdown HT1080 cells and control HT1080 cells, we found that ZFP57 
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knockdown reduces AKT phosphorylation (Figure 4c), suggesting that 
ZFP57-stimulated IGF2 upregulation leads to AKT activation in HT1080 cells.   
To examine the requirement of IGF2 in anchorage-independent growth in 
HT1080 cells, we inhibited IGF2 activity with an anti-IGF2 neutralizing antibody.  As 
shown in Figure 4d, the neutralizing antibody strongly suppressed 
anchorage-independent growth.  Similar results were obtained with knockdown 
experiments (Figure S6).  Furthermore, the neutralizing antibody suppressed the 
ZFP57-induced anchorage-independent growth of HT1080 cells (Figure 4e).   
We also examined the requirement of IGF2 in tumor formation by xenograft 
assay (Figure 4f).  When IGF2 knockdown HT1080 cells were implanted into nude 
mice, IGF2 knockdown significantly inhibited tumor formation.  Moreover, we found 
that IGF2 knockdown attenuates the enhanced tumor growth by Zfp57 overexpression 
(Figure 4g and supplementary Figure S7). 
These results suggest that IGF2 is a key molecule in ZFP57-mediated 
anchorage-independent growth.   
 
Zfp57 is involved in the anchorage-independent growth of ES cells 
ES cells can grow in anchorage-independent conditions, as expected from the fact that 
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they can give rise to benign tumors called teratomas when injected into 
immunodeficient mice.3  Previously, we established Zfp57 knockout ES cells and 
showed that Zfp57 is dispensable for ES cell self-renewal and proliferation in 
anchorage-dependent conditions.30  Since we found here that ZFP57 is involved in 
anchorage-independent growth in HT1080 cells, we examined whether this was true in 
ES cells.  To assess the effect of Zfp57 level on the colony-forming capacity of ES 
cells in soft agar, we compared 1F9 cells (Zfp57+/- ES cells that express Zfp57) to 2E9 
cells (Zfp57-/- ES cells that lost expression of Zfp57).30  Both cells were seeded into 
soft agar and allowed to grow.  About 1 week later, we observed that the number of 
viable 2E9 colonies was significantly lower than that of viable 1F9 colonies (Figure 5), 
suggesting that Zfp57 is involved in anchorage-independent growth in ES cells.  We 
confirmed that the reduction in colony number can be recovered by overexpression of 
exogeneous Zfp57 (Supplementary Figure S8).  These results further suggest that 
ZFP57 plays an important role in anchorage-independent growth.   
 
ZFP57 transforms NIH3T3 cells  
The importance of ZFP57 in anchorage-independent growth encouraged us to explore 
the possibility that ZFP57 may be an oncogene.  The immortal mouse fibroblast cell 
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line NIH3T3 can hardly grow in an anchorage-independent manner and has been used 
to evaluate the transforming activity of individual genes.   
To determine whether ZFP57 has transforming potential, we overexpressed 
ZFP57 in NIH3T3 cells and performed a soft agar assay.  As shown in Figure 6, 
colony formation in soft agar by parental NIH3T3 cells was very ineffective.  By 
contrast, ZFP57 overexpression allowed NIH3T3 cells to grow efficiently in soft agar, 
suggesting that ZFP57 possesses oncogenic properties.   
 
ZFP57 expression in cancer patients 
Finally, we investigated the expression of ZFP57 in patients with different kinds of 
cancers by immunohistochemical staining.  When compared to normal tissues, we 
observed the overexpression of ZFP57 in several cancer tissues (Figure 7, Table I).  In 
pancreatic cancer, more than 70% of the patients tested were positive for ZFP57.  In 
gastric, breast, colon and esophageal cancer tissues, about 40% of the patients were 
ZFP57-positive.  By contrast, ZFP57 overexpression was rarely observed in 
hepatocellular carcinoma and cholangiocellular carcinoma tissues.  The specificity of 
anti-human ZFP57 antibody was confirmed by Western blotting (Supplementary Figure 
S9).  These results suggest that ZFP57 functions as an oncogene in some human 
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cancers.   
 Moreover, we performed immunohistochemical staining using anti-IGF2 
antibody (Supplementary Figure S10) and found a statistically significant correlation 
between ZFP57 and IGF2 expression in esophageal and breast cancers (P=0.03169 and 
0.00617, respectively, Chi-square test).  No significant correlation was observed in 
other cancers.  These results suggest that ZFP57 overexpression leads to IGF-2 





The transcription factor Zfp57 was originally identified as an undifferentiated 
cell-specific gene in F9 embryonal carcinoma cells.31  The mouse ZFP57 protein 
consists of 421 amino acids and contains one Kruppel-associated box (KRAB) domain 
and five zinc fingers, while the human ZFP57 protein consists of 536 amino acids with 
one KRAB domain and seven zinc fingers.  In ES cells, Zfp57 is downstream of Stat3 
and Oct3/4, and therefore shows self-renewal-specific expression.30  In adult mouse 
organs, Zfp57 is highly expressed in testis and brain.31,32  Loss of the zygotic function 
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of Zfp57 causes partial lethality, while eliminating both the maternal and zygotic 
functions of Zfp57 leads to complete embryonic lethality.26  Several reports have 
suggested that this transcription factor binds to KRAB-associated protein 1 (KAP1), a 
scaffold protein for various heterochromatin-inducing factors, through its KRAB 
domain, and is involved in genome imprinting by recruiting KAP1 to several 
ICRs.26,27,33  In addition, mutations in the ZFP57 gene result in transient neonatal 
diabetes mellitus type 1, possibly through Plagl1 overexpression.34,35  The role of 
ZFP57 in tumorigenesis has not been elucidated yet.   
In this study, we demonstrated the involvement of ZFP57 in the 
anchorage-independent growth of tumor cells both in vitro and in vivo.  When cultured 
in the absence of adhesion to substratum, normal adherent cells undergo apoptosis, a 
phenomenon known as anoikis.36,37  By contrast, transformed cells are able to survive 
and grow even in the absence of anchorage.  Anchorage-independent growth is 
therefore a major characteristic of transformed cells, and in fact shows a good 
correlation with tumor malignancy.38,39  In addition to cancer cells, Zfp57 is involved 
in ES cell anchorage-independent growth, suggesting that ZFP57-mediated 
anchorage-independent growth is not restricted to cancer cells.  Furthermore, ZFP57 
enables immortal NIH3T3 fibroblasts to proliferate independently of anchorage.  
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These results strongly suggest that ZFP57 plays an important role in 
anchorage-independent growth.  
We demonstrated that, as a molecule downstream of ZFP57, IGF2 plays a 
critical role in anchorage-independent growth in HT1080 cells.  To promote cell 
proliferation, IGF2 binds to the IGF1 receptor and stimulates PI3 kinase activity, 
leading to the activation of AKT.  It is well-known that AKT activation plays an 
important role in anchorage-independent growth in cancer cells.37  We confirmed the 
expression of the IGF1 receptor and observed that IGF2 stimulation leads to activation 
of AKT in HT1080 cells.  Furthermore, we found that ZFP57 knockdown reduces 
AKT phosphorylation.  These observations suggest that ZFP57-induced IGF2 
stimulates HT1080 cells in an autocrine manner and activates the AKT pathway to 
avoid anoikis and promote anchorage-independent growth. 
Although overexpression of IGF2 is observed in a variety of cancer cells,40 its 
molecular mechanism is not fully understood.  A well-known mechanism is loss of 
imprinting.  In normal cells, IGF2 expression is regulated by genome imprinting and 
transcription of IGF2 mRNA occurs only at the paternal allele.  In some cancer cells, 
however, this imprinting system is not functional and IGF2 mRNA is transcribed from 
both alleles, resulting in increased expression of IGF2.  Imprinting of IGF2 is 
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regulated at the IGF2-H19 ICR, and ZFP57 binds to this region in ES cells.27  In this 
study, we also observed the binding of ZFP57 to the IGF2-H19 ICR in HT1080 cells.  
It is possible therefore that ZFP57 regulates IGF2 expression through loss of imprinting 
in HT1080 cells, although the previous finding that Zfp57 deficiency has no effect on 
the expression level of Igf2 in mouse embryo cells does not support this possibility.26   
Our preliminary analysis using bisulfite sequencing suggests that DNA methylation 
level around the ZFP57-binding region of IGF2-H19 ICR is low in HT1080 cells, also 
diminishing this possibility.  Another mechanism of IGF2 overexpression is through 
activation of the IGF2 promoter.  For example, E2F3 activates the IGF2 promoter and 
overexpression of E2F3 correlates with IGF2 overexpression in prostate and bladder 
cancers,41 suggesting that IGF2 expression in cancer cells is modulated not only by 
imprinting, but also by regulation of IGF2 promoter activity.  We are now 
investigating which mechanism of IGF2 upregulation is employed by ZFP57.  
Since ZFP57 regulates the expression of various imprinted genes and since the 
aberrant regulation of imprinted genes causes tumorigenesis,42,43 it is possible that other 
imprinted genes, in addition to IGF2, may function downstream of ZFP57 to promote 
tumorigenesis.  Interestingly, we have already found that ZFP57 regulates the 
expression of Delta-like homolog 1 (DLK1) in HT1080 cells (Tada et al., unpublished 
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data).  An imprinted gene, DLK1, is a non-canonical Notch ligand that plays an 
important role in the growth of several tumors including neuroblastoma and 
hepatoblastoma.44  It is possible therefore that DLK1 may be another key imprinted 
gene in ZFP57-stimulated cancer growth.  In addition, non-coding RNAs are possible 
target genes of ZFP57, since multiple non-coding RNAs are located in the imprinted 
locus and are involved in tumorigenesis.45-47  Identification of another ZFP57 target 
gene would be of great help to understand the molecular mechanism of ZFP57-induced 
tumor growth in more detail. 
In conclusion, we demonstrated here that the ES-specific transcription factor 
ZFP57 promotes anchorage-independent growth in HT1080 cells by upregulating IGF2 
expression.  In addition, ZFP57 enables normal mouse fibroblasts to grow even in the 
absence of anchorage.  Furthermore, we observed the overexpression of ZFP57 in 
multiple types of cancers.  Our data suggest that ZFP57 can function as an oncogene.  
Our present findings raise several intriguing possibilities.  Firstly, since ZFP57 is 
overexpressed in several tumors, together with the previous findings that ZFP57 is 
involved in imprinting, it is possible that aberrant regulation of ZFP57 may cause loss 
of imprinting in some types of cancers.  Secondly, considering that ZFP57 is a stem 
cell-specific transcription factor involved in tumor growth, it is possible that ZFP57 
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may be expressed in cancer stem cells and play a role in their growth.  Thirdly, since 
induced pluripotent stem (iPS) cells have a similar gene expression profile to ES cells,48 
it is likely that ZFP57 is expressed in iPS cells.  Considering that ZFP57 has 
transforming ability, it is possible that the high expression of ZFP57 in iPS cells may 
increase the risk of tumor formation during cell therapy using iPS-derived cells.  These 
possibilities will be explored in a future study. 
 
 
Materials and methods 
 
Cell lines and antibodies 
HT1080 fibrosarcoma cells and HEK293 cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal 
bovine serum.  NIH3T3 cells were cultured in DMEM containing 10% fetal calf serum.  
ES cells were cultured on gelatin-coated dishes with LIF-supplemented DMEM as 
described previously,49 except that the culture medium contained 150 µM 1-thioglycerol 
(Wako Pure Chemical Industries, Osaka, Japan) instead of 40 µM β-mercaptoethanol.  
All cell lines were maintained in a humidified atmosphere of 5% CO2. 
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Anti-IGF2 neutralizing antibody (clone S1F2) was purchased from Millipore 
(Billerica, MA, USA).  Control IgG (ab37355) was from Abcam (Cambridge, MA, 
USA).  Anti-myc antibody (clone 9E10) and anti-α-tubulin antibody (clone 2F9) were 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and MBL (Nagoya, Japan), 
respectively.  Antibodies against AKT (#4691), phospho-AKT (Thr308) (#2965), 
phospho-AKT (Ser473) (#4060) and the IGF1 receptor (#9750) were from Cell 
Signaling Technology (Boston, MA, USA). 
 
Plasmid construction 
The coding sequences of human and mouse ZFP57 (NCBI accession numbers: 
NM_001109809 and NM_009559, respectively) were amplified from cDNA 
synthesized from HT1080 cell total RNA and A3-1 ES cell total RNA, respectively, 
using primers listed in Supplementary Table S1.  pCAGIP-myc-hZFP57, 
pCAGIP-HA-hZFP57 and pCAGIP-Flag-hZFP57 were constructed by inserting a myc-, 
HA- or flag-tagged human ZFP57 coding fragment into the mammalian expression 
vector pCAG-IP.49  Plasmid pCAG-IH3 was constructed by replacing the sequence of 
internal ribosomal entry site (IRES) and the puromycin-resistance gene of pCAG-IP 
with that of IRES and the hygromycin-resistance gene of pIRES-hyg3 (Clontech, Palo 
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Alto, CA, USA).  Plasmid pCAG-IN3 was constructed by inserting the CAG promoter 
of pCAG-IP into pIRES-neo2 (Clontech).  Plasmids pCAGIH3-mZfp57 and 
pCAGIN3-myc-mZfp57 were produced by inserting a mouse Zfp57 coding fragment 
and a myc-tagged mouse Zfp57 coding fragment into pCAG-IH3 and pCAG-IN3, 
respectively.  To construct the episomal expression vector pEBM-CAGIP, EBNA1 
cDNA and the OriP sequence of Epstein-Barr virus were transferred from 
pEBMulti-Neo (Wako Pure Chemical Industries) to pCAG-IP.  The coding region of 
the ligand-binding domain of the estrogen receptor was inserted into 
pCAGPMN(PvuII-MfeI)-CreER, a kind gift from Dr. Chuanhai Sun, to produce 
pCAG-myc-ER-Cre-ER. 
For knockdown experiments by RNA interference, oligonucleotides containing 
target sequences for ZFP57 [5’-GGTCCTTTACCAGGATGTTAT-3’ for ZFP57(349); 
5’-GCTAATCACCAAGCTTGAGCA-3’ for ZFP57(427)] and IGF2 
[5’-GCTGGTGCTTCTCACCTTCTT-3’ for IGF2(779)] were introduced into the 
miRNA expression vector pcDNA6.2-GW/EmGFPmiR (Invitrogen, Carlsbad, CA, 
USA) to obtain pGW/EmGFP-ZFP57(349 or 427) and pGW/EmGFP-IGF2(779), 
respectively (Supplementary Table S1).  EmGFP-control miRNA, EmGFP-ZFP57 
miRNA(349 or 427) and EmGFP-IGF2 miRNA(779) were transferred from 
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pGW/EmGFP constructs to pEBM-CAGIP to obtain pEBM-CAGIP-EmGFP-control, 
pEBM-CAGIP-EmGFP-ZFP57(349 or 427) and pEBM-CAGIP-EmGFP-IGF2(779), 
respectively.  The plasmid pCAG-IG1a was constructed by replacing the 
IRES-puromycin resistance gene of pCAG-IP with IRES-hrGFP1a in pIRES-hrGF1a 
(Stratagene, La Jolla, CA, USA).  An inducible expression vector, pCALiPL-IG1a, 
was constructed by inserting a loxP-IRES-puromycin resistance-loxP cassette into 
pCAG-IG1a.  EmGFP-ZFP57 miRNA(427) was transferred from 
pGW/EmGFP-ZFP57(427) into pCALiPL-IG1a to produce 
pCALiPL-IG1a-EmGFP-hZFP57(427). 
 
Establishment of stable cell lines 
To establish ZFP57-overexpressing HT1080 cells, HT1080 cells were transfected with 
pCAGIP-myc-hZFP57 using Lipofectamine 2000 (Invitrogen) and selected with 0.3 
µg/ml puromycin for 2 weeks.  Resistant clones were pooled and subjected to 
experiments.  Similarly, HT1080 cells were transfected with pEBM-CAGIP-EmGFP 
constructs to obtain HT1080 cells with ZFP57 knockdown. 
To establish the cell line with inducible ZFP57 knockdown 
HT1080/pCALiPL-ZFP57(427), HT1080 cells were transfected with both 
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pCALiPL-IG1a-EmGFP-hZFP57(427) and pCAG-myc-ER-Cre-ER, and selected with 




Total RNA was extracted from individual cultured cells using Sepasol RNA I super G 
(Nacalai Tesque), and cDNA synthesis was performed with ReverTra Ace (Toyobo, 
Osaka, Japan).  Real-time PCR analysis using SYBR green was conducted using the 
Mx3000p System (Stratagene), and results were normalized to β-actin expression.  
Primers are listed in Supplementary Table S1. 
 
Western blot analysis  
Cells were lysed in cell lysis buffer [20 mM Hepes-NaOH (pH 7.2), 10 mM MgCl2, 1 
mM EDTA, 10 mM sodium fluoride, 25 mM β-glycerophosphate, 1 mM sodium 
orthovanadate, 20 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml pepstatin A, 1% 
Nonidet P-40, and 10% glycerol].  Lysates were then mixed with 1X sample buffer 
[6% glycerol, 10 mM Tris–HCl (pH 6.8), 2% SDS, 50 mM DTT, 2 mM EDTA, and 
0.002% Coomassie Brilliant Blue R250] and heat-denatured.  Samples were subjected 
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to SDS-PAGE and electrophoretically transferred to nitrocellulose membranes.  The 
membranes were then probed with antibodies, and signals were visualized using 
enhanced chemiluminescence reagents (Perkin-Elmer, Norwalk, CT, USA) with the 
LAS-1000 image analyzer (Fuji Film, Tokyo, Japan).  In all experiments, α-tubulin 
was used as an internal control.   
 
Soft agar assay and xenograft experiments  
For soft agar assays, cells were seeded in 2.4 ml of culture medium containing 0.5% Sea 
Plaque agarose (Lonza, Rockland, ME, USA), overlaid on 3 ml of 0.53% agarose in 6 
cm dishes.  The cultures were maintained for about 2 weeks.  Viable colonies were 
stained with 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(Nacalai Tesque).  Dishes were then scanned with an ES-2200 scanner (EPSON, 
Nagano, Japan), and the number of stained colonies was counted by Image-J (NIH, 
Bethesda, MD, USA). 
The tumorigenic potential of HT1080/pCALiPL-ZFP57 cells was assessed in 
10 CAnN,Cg-Foxn1nu/CrlCrlj mice at 3 weeks of age (Charles River, Wilmington, MA, 
USA).  After a 3 day treatment with ethanol or 4-HT, HT1080/pCALiPL-ZFP57 cells 
(1 × 107 cells/ml) were resuspended in the culture medium, and one million cells were 
23 
 
injected subcutaneously into mice.  Animals were sacrificed 2 weeks after injection.  
Tumors were dissected and photographed.  All procedures were conducted in 
accordance with the Fundamental Guidelines for Proper Conduct of Animal Experiment 
and Related Activities in Academic Research Institutions under the jurisdiction of the 
Ministry of Education, Culture, Sports, Science and Technology of Japan and approved 
by the Committee on Animal Experimentation of Kanazawa University. 
 
Chromatin immunoprecipitation (ChIP) assay 
HT1080 cells were transfected with pCAGIP-Flag-hZFP57 and cultured for 2 days.  
After harvest, cells were processed for ChIP assay using the OneDay ChIP kit (Nippon 
Gene, Tokyo, Japan).  Briefly, cells were fixed with 1% formaldehyde for 10 min at 
room temperature and the chromatin was sheared to an average fragment size of 500?
1000 bp by sonication with a Bioruptor (Cosmo Bio, Tokyo, Japan).  After 
cross-linking was quenched with glycine, whole cell extracts were prepared for 
chromatin immunoprecipitation.  Fragmented chromatin was used in each reaction.  
DNA was immunoprecipitated with 5 µg of anti-flag antibody (M2; Sigma) or normal 
mouse IgG (sc-2025; Santa Cruz).  DNA from the immunoprecipitates or from 1% of 
the input material was analyzed by PCR using primers specific for the IGF2-H19 ICR 
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(Supplementary Table S1).  
 
Immunohistochemical analysis 
The expressions of ZFP57 and IGF2 in carcinomas were examined 
immunohistochemically using the EnVision+ System (DAKO, Copenhagen, Denmark).  
Tumor specimens were fixed in 10% formalin and embedded in paraffin.  Dewaxed 4 
µm sections were incubated with protein-blocking serum for 10 min to block 
non-specific binding.  The sections were then incubated with rabbit anti-human ZFP57 
polyclonal antibody (U-18; Santa Cruz Biotechnology) (1:50) or rabbit anti-human 
IGF2 polyclonal antibody (LS-B7415; LifeSpan Biosciences, Seattle, WA, USA) (5 
µg/ml) at 4˚C overnight.  After washing, EnVision+ polymer solution was applied for 
1 hour.  The reaction products were visualized with diaminobenzidine.  The 
specimens were then lightly counterstained with hematoxylin.   Written consent was 
obtained from all patients, and the project was approved by the Ethics Committee for 
Human Genome/Gene Analysis Research at Kanazawa University Graduate School of 
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Figure 1.  ZFP57 is involved in anchorage-independent growth in HT1080 cells.  
(a-c) Overexpression of ZFP57 promotes anchorage-independent growth in HT1080 
cells.  HT1080 cells were transfected with either pCAGIP-myc (Control) or 
pCAGIP-myc-hZFP57(ZFP57), selected with puromycin, and subjected to soft agar 
assay.  (a) Scanned images of HT1080 cell soft agar plates stained with MTT.  
Representative images of three independent experiments are shown.  (b) The number 
of stained colonies was counted using the Image-J software.  The number of colonies 
in control cells was set to 1.0, and data are shown as the mean ± standard deviation 
(n=3).  *, P<0.05.  (c) Western blot analysis using anti-myc antibody showing 
expression of myc-tagged human ZFP57 (Myc-ZFP57) in HT1080 cells.  (d) 
Knockdown of ZFP57 inhibits anchorage-independent growth in HT1080 cells.  
HT1080 cells were transfected with pEBM-CAGIP-EmGFP-control miRNA, 
pEBM-CAGIP-EmGFP-ZFP57(349) or pEBM-CAGIP-EmGFP-ZFP57(427) and 
subjected to soft agar assay after puromycin selection.  Error bars represent standard 
deviation [n=3 for ZFP57(349), n=4 for ZFP57(427)].  *, P<0.05.   
 
Figure 2.  ZFP57 is required for tumorigenicity in HT1080 cells in vivo.  (a) 
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Knockdown of ZFP57 reduces HT1080 tumor growth in nude mice.  
HT1080/pCALiPL-ZFP57(427) cells were pretreated with ethanol vehicle (EtOH) or 
4-HT and injected subcutaneously into mice.  Note that 4-HT pretreatment results in 
suppression of endogenous ZFP57 in HT1080/pCALiPL-ZFP57(427) cells.  (b) 
Overexpression of ZFP57 promotes HT1080 tumor formation in nude mice.  HT1080 
cells were transfected with pCAGIP-myc (Control) or pCAGIP-myc-hZFP57(ZFP57), 
and puromycin-resistant clones were injected subcutaneously.  In both experiments, 
mice were sacrificed 2 weeks after injection, and tumor volume was measured.  
Median values are represented by horizontal bars.  *, P<0.05 by Mann-Whitney test. 
 
Figure 3.  ZFP57 regulates IGF2 expression.  (a) ZFP57 binds to IGF2-H19 ICR in 
vivo.  HT1080 cells transfected with either pCAGIP-Flag (Control) or 
pCAGIP-Flag-hZFP57 (ZFP57) were subjected to ChIP assay using anti-flag antibody 
with primers specific for the ZFP57-binding region of the IGF2-H19 ICR.  Data shown 
are representative data of three separate experiments.  (b) IGF2 expression is 
downregulated by knockdown of ZFP57.  HT1080 cells constitutively expressing 
either control or ZFP57 miRNA were generated by transfecting pEBM-CAGIP 
constructs, and IGF2 and ZFP57 mRNA expression levels were measured by 
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quantitative RT-PCR.  The expression levels of IGF2 and ZFP57 in control cells were 
set to 1.0.  Error bars indicate standard deviation in triplicate samples.  *, P<0.05.  
Representative data of three independent experiments are shown. 
 
Figure 4.  IGF2 is required for anchorage-independent growth in HT1080 cells.  (a) 
The IGF1 receptor is expressed in HT1080 cells.  Expression of the IGF1 receptor 
(IGF1r) was examined by Western blot analysis.  HEK293 cells were used as a 
positive control.  (b) IGF2 induces the activation of AKT.  HT1080 cells were 
starved overnight in serum-free medium supplemented with 0.1% bovine serum 
albumin, and then stimulated for 15 min with recombinant IGF2 protein (100ng/ml) 
(Bay bioscience, Kobe, Japan).  (c) ZFP57 knockdown reduces AKT phosphorylation.  
HT1080 cells transfected with either control vector or ZFP57 miRNA-expression vector 
were cultured in the presence of 10% fetal bovine serum for 3 days.   In both 
experiments, cells were harvested, lysed, and subjected to Western blot analysis.  
Representative data from three independent experiments are shown.  (d) IGF2 
neutralizing antibody suppresses anchorage-independent growth in HT1080 cells.  
Neutralizing antibody was added to the top layer at the concentration of 10 µg/ml.  (e) 
IGF2 neutralization abolishes ZFP57-mediated growth in soft agar.  HT1080 cells 
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were transfected with ZFP57 and subjected to soft agar assay in the presence or absence 
of the IGF2 neutralizing antibody.  In both experiments, the number of colonies in 
control cells was set to 1.0, and error bars represent standard deviation (n=3).  *, 
P<0.05.  (f) Knockdown of IGF2 reduces HT1080 tumor growth in nude mice.  
HT1080 cells were transfected with pEBM-CAGIP-EmGFP-IGF2(779), and 
puromycin-resistant clones were injected into nude mice subcutaneously.  Mice were 
sacrificed 2 weeks after injection, and tumor volume was measured.  (g) IGF2 
knockdown attenuates the enhanced tumor growth due to Zfp57 overexpression.  
HT1080 cells expressing IGF2 miRNA were transfected with pCAGIH3-mZfp57, and 
hygromycin-resistant clones were injected subcutaneously.  Mice were sacrificed 9 
days after injection to measure tumor volume.  In both experiments, median values are 
represented by horizontal bars.  *, P<0.05 by Mann-Whitney test. 
 
Figure 5.  Zfp57 is involved in anchorage-independent growth in ES cells.  1F9 cells 
[Zfp57(+/-)] and 2E9 cells [Zfp57(-/-)] were subjected to soft agar assay.  (a) 
Representative scans of ES cell soft agar plates stained with MTT.  (b) The number of 
stained colonies was counted using the Image-J software.  The colony number in 1F9 




Figure 6.  Overexpression of ZFP57 induces anchorage-independent growth in 
NIH3T3 cells.  NIH3T3 cells were transfected with pCAGIP-myc (Control) or 
pCAGIP-myc-hZFP57 (ZFP57), and subjected to soft agar assay.  (a) Representative 
scans of NIH3T3 cell soft agar plates stained with MTT.  (b) The number of stained 
colonies was counted using the Image-J software.  Error bars represent standard 
deviation (n=3).  *, P<0.05.  (c) Western blot analysis using anti-myc antibody 
showing myc-tagged human ZFP57 expression in NIH3T3 cells. 
 
Figure 7.  ZFP57 is overexpressed in tumor tissues. 
Immunohistochemical staining of ZFP57 expression in pancreatic (a) and esophageal 
(b) tumors and normal tissues.  Representative images are shown.  The arrows 
indicate ZFP57-positive cells.  
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Table I.  ZFP57 overexpression in tumor specimens from cancer patients.  
 
 
  Primary site (carcinoma)    No. of patients No. of ZFP57-positive (%) 
  Pancreatic cancer   15   11 (73%) 
  Gastric cancer    20    9 (45%) 
  Breast cancer    20    8 (40%) 
  Colorectal cancer   20    8 (40%) 
  Esophageal cancer   20    7 (35%) 
  Hepatocellular carcinoma  20    1 (5.0%) 











 “The stem cell transcription factor ZFP57 induces IGF2 expression to 
promote anchorage-independent growth in cancer cells.” by Tada, Y. et al. 
  
Table S1 Sequences of used primers and oligonucleotides
Primers for cloning
Gene Name Forward Primer (5' to 3') Reverse Primer (5' to 3') 
human ZFP57 GATATCATGTTTGAACAGCTGAAGCC GCGGCCGCTTATTTATGTTTCAAGATGC
mouse Zfp57 GAATTCATGGCAGCTAGGAAACAGTCTTCC GCGGCCGCTCAGTCCGAATCTTCTTC
Primers for regular RT-PCR and quantitative RT-PCR
Gene Name Forward Primer (5' to 3') Reverse Primer (5' to 3') 
human ZFP57 AAGCCAGAGGTCCATCCAG GGGCAACAGAAGACATTGAG
IGF2 GTGGCATCGTTGAGGAGTG GGGTGGGTAGAGCAATCAGG
β-actin AAACTGGAACGGTGAAGGTG GTGGACTTGGGAGAGGACTG
mouse Zfp57 GAATTCTGTAATTTCTGTGGCAAGAC GCGGCCGCTGTGGATCTTGAGGTGGGTTAA
G3PDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA
Primers for ChIP analysis
Gene Name Forward Primer (5' to 3') Reverse Primer (5' to 3') 
IGF2-H19 ICR TGGCAGGCACAGAAACTG GAGCGTCCTATTCCCAGAAG
Oligonucleotides for miRNA vector construction
Gene Name Forward Primer (5' to 3') Reverse Primer (5' to 3') 
ZFP57(349) TGCTGATAACATCCTGGTAAAGGACCGTTTTGGCCACTGACTGACGGTCCTTTCAGGATGTTAT CCTGATAACATCCTGAAAGGACCGTCAGTCAGTGGCCAAAACGGTCCTTTACCAGGATGTTATC
ZFP57(427) TGCTGTGCTCAAGCTTGGTGATTAGCGTTTTGGCCACTGACTGACGCTAATCAAAGCTTGAGCA CCTGTGCTCAAGCTTTGATTAGCGTCAGTCAGTGGCCAAAACGCTAATCACCAAGCTTGAGCAC 
IGF2(779) TGCTGAAGAAGGTGAGAAGCACCAGCGTTTTGGCCACTGACTGACGCTGGTGCCTCACCTTCTT CCTGAAGAAGGTGAGGCACCAGCGTCAGTCAGTGGCCAAAACGCTGGTGCTTCTCACCTTCTTC 
Legends for supplementary figures 
 
Figure S1.  Search for ES-specific genes that promote anchorage-independent growth 
in HT1080 cells.  HT1080 cells were transfected with either an empty vector or 
expression vectors encoding the indicated genes, which were cloned from mouse ES 
cells.  Puromycin-resistant clones were then pooled and subjected to soft agar assay.  
Black and gray bars show the data of the 1st and 2nd experiments, respectively.  The 
numbers of colonies in control cells were set to 1.0 (indicated by red line).  The 
expression vector for Klf4 was kindly provided by Dr. Hitoshi Niwa.  
 
Figure S2.  Overexpression of Zfp57 recovers the reduced anchorage-independent 
growth of ZFP57 knockdown HT1080 cells.  (a) Soft agar assay.  HT1080 cells 
expressing ZFP57 miRNA(427) were transfected with empty vector (control) or 
pCAGIN3-myc-mZfp57 (Zfp57), and selected by the presence of G418.  Resistant 
clones were then subjected to soft agar assay.  The number of stained colonies in 
control cells was set to 1.0.  Error bars represent standard deviation (n=3).  *, P<0.05.  
(b) Expression of exogenous mouse Zfp57 was confirmed by regular RT-PCR.  
Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) was used as an internal control.   
Primers used for RT-PCR are listed in Supplementary Table S1. 
 
Figure S3.  Establishment of HT1080/pCALiPL-ZFP57(427) cells.  (a) Strategy of 
inducible ZFP57 knockdown.  Since HT1080/pCALiPL-ZFP57(427) cells express 
ER-Cre-ER, a fusion protein between Cre recombinase and the ligand-binding domain 
of the estrogen receptor, 4-hydroxytamoxifen (4-HT) treatment stimulates Cre-mediated 
recombination, leading to deletion of the region between loxP sites.  As a result, 
expression of EmGFP and ZFP57 miRNA is induced.  (b) Treatment with 4-HT 
reduces ZFP57 expression in HT1080/pCALiPL-ZFP57(427) cells.  
HT1080/pCALiPL-ZFP57 miRNA cells were cultured in the presence of ethanol 
vehicle (EtOH) or 1 µM 4-HT, and subjected to quantitative RT-PCR.  The expression 
level of ZFP57 in control cells (i.e., ethanol-treated cells) was set to 1.0.  Error bars 
indicate standard deviation in triplicate samples.  *, P<0.05.  Representative data 
from three independent experiments are shown.  (c) Knockdown of ZFP57 reduces the 
anchorage independence of HT1080 cells.  HT1080/pCALiPL-ZFP57 miRNA cells 
were subjected to soft agar assay in the presence of ethanol vehicle (EtOH) or 4-HT.  
The number of stained colonies in control cells was set to 1.0.  Error bars represent 
standard deviation (n=3).  *, P<0.05. 
 Figure S4.  ZFP57 expression in resulting tumors.  RNA was prepared from three 
control HT1080-derived tumors and three ZFP57-overexpressing HT1080-derived 
tumors and subjected to quantitative RT-PCR to determine the expression level of 
ZFP57 in each tumor.  The expression level of ZFP57 in control cells (#1) was set to 
1.0.  Error bars indicate standard deviation in triplicate samples. 
 
Figure S5.  Overexpression of Zfp57 rescues the reduced IGF2 expression in ZFP57 
knockdown HT1080 cells.  (a) Recovery of IGF2 expression by Zfp57 overexpression.  
After transfection with empty vector (control) or pCAGIH3-mZfp57 (Zfp57), ZFP57 
knockdown HT1080 cells were subjected to quantitative RT-PCR to determine the 
expression level of IGF2.  The expression level of IGF2 in control cells was set to 1.0.  
Error bars indicate standard deviation in triplicate samples.  *, P<0.05.  (b) 
Confirmation of exogenous mouse Zfp57 expression by regular RT-PCR.   
  
Figure S6.  IGF2 is required for anchorage-independent growth in HT1080 cells.  (a) 
Knockdown of IGF2 inhibits anchorage-independent growth in HT1080 cells.  Error 
bars represent standard deviation (n=3).  *, P<0.05.  (b) Downregulation of IGF2 
expression upon IGF2 knockdown.  The expression level of IGF2 in control cells was 
set to 1.0.  Error bars indicate standard deviation in triplicate samples.  *, P<0.05.  
Representative data from three independent experiments are shown.  HT1080 cells 
were transfected with pEBM-CAGIP-EmGFP-control or 
pEBM-CAGIP-EmGFP-IGF2(779), and subjected to soft agar assay and quantitative 
RT-PCR after puromycin selection.   
 
Figure S7.  Zfp57 expression in HT1080 transfectants.  HT1080 transfectants were 
subjected to regular RT-PCR to confirm the expression of exogenous mouse Zfp57.   
 
Figure S8.  Zfp57 overexpression restores the reduced anchorage-independent growth 
of Zfp57-null ES cells.  (a) 1F9 cells and 2E9 cells were transfected with empty vector 
(control) or pCAGIP-myc-Zfp57 (Zfp57).  After selection with puromycin, cells were 
subjected to soft agar assay.  The number of colonies in 1F9 cells was set to 1.0, and 
error bars represent standard deviation (n=3).  *, P<0.05.  (b) Expression of 
endogenous and exogenous mouse ZFP57 protein.  Cell lysates were subjected to 
immunoblot analysis with an antibody against mouse ZFP57 antibody.30  Note that 
myc-tagged ZFP57 shows slightly slower mobility than endogenous ZFP57. 
 Figure S9.  Western blotting analysis of ZFP57.  Cell lysates were prepared from 
HEK293 cells transfected with either control vector (control) or pCAGIP-HA-hZFP57 
(hZFP57) and subjected to Western blot analysis with anti-hZFP57 antibody (upper 
panel) and anti-α-tubulin antibody (lower panel). 
  
Figure S10.  Immunohistochemical staining of IGF2 expression in breast (a) and 
esophageal (b) tumors and normal tissues.  Representative images are shown.   
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